
29 Sep 2025
4basebio - 1H25 Interims: Looking beyond nearer-term headwinds
4basebio (4BB) has reported its 1H25 results to 30 June 2025 with revenue growth during the period providing us with a degree of confidence that industry adoption of synthetic DNA is beginning to accelerate. 1H25 revenues of £1.2m were nearly four times higher than 1H24 (1H24: £0.3m) and c25% above the full year 2024 (FY24: £0.9m). 1H25 period end cash was £26.1m (FY24: £34.6m) providing a multi-year runway to support scaling and execution of 4BB’s commercialisation strategy. In our view, the re ....

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
4basebio - 1H25 Interims: Looking beyond nearer-term headwinds
4basebio PLC (4BB:LON) | 775 0 0.0% | Mkt Cap: 120.4m
- Published:
29 Sep 2025 -
Author:
Adam McCarter -
Pages:
12 -
4basebio (4BB) has reported its 1H25 results to 30 June 2025 with revenue growth during the period providing us with a degree of confidence that industry adoption of synthetic DNA is beginning to accelerate. 1H25 revenues of £1.2m were nearly four times higher than 1H24 (1H24: £0.3m) and c25% above the full year 2024 (FY24: £0.9m). 1H25 period end cash was £26.1m (FY24: £34.6m) providing a multi-year runway to support scaling and execution of 4BB’s commercialisation strategy. In our view, the re ....